The ACC, AHA, and nine other associations have issued an updated dyslipidemia guideline, recommending earlier intervention and expanded use of lipoprotein(a) and apolipoprotein B testing to improve cardiovascular risk assessment.
Roche’s Tina-quant Lp(a) Gen.2 Molarity assay received FDA 510(k) clearance, supporting more precise cardiovascular risk assessment.
AMPEL BioSolutions’ new CardioGENE blood test predicts heart disease by identifying genetic markers and inflammatory pathways.
Researchers developed a POC electrochemical biosensor prototype designed to provide at-home screening capabilities for heart failure.
Read More
A study reveals that lipid panels may not fully capture the risk of cholesterol-related heart disease, highlighting a need for apoB testing.
Read More
Prevencio received a patent for its AI-powered blood test which accurately assesses the risk of obstructive coronary artery disease.
Read More
Researchers developed a machine learning method that utilizes deep learning and video microscopy to automate the analysis of heart dynamics.
Read More
Siemens Healthineers introduced the NT-proBNPII assay to its Atellica Solution, enhancing rapid diagnostic capabilities for heart failure.
Read More
Roche announced that its Tina-quant lipoprotein Lp(a) RxDx assay received Breakthrough Device Designation from the FDA.
Read More
Researchers developed a genetic testing procedure that can identify patients at high risk for cardiovascular diseases.
Read More
Analytics for Life and CorVista Health announced U.S. FDA clearance of the CorVista System with Pulmonary Hypertension (PH) Add-On Module
Read More
The new high-sensitivity troponin assay is designed for use on the the PATHFAST Biomarker Analyzer from Polymedco.
Read More
Bodyport says its biomarker-based technology for remote heart failure monitoring detected twice as many heart failure events.
Read More
The measurement of six blood biomarkers improved the ability of researchers to predict a future increase in arterial inflammation.Â
Read More
Combining the results of a standard blood test and an online tool can help identify those who are at risk of having a heart attack.
Read More
Researchers extracted data on 321 biomarkers and found 13 were significantly associated with cardiovascular risk in type 2 diabetes patients.
Read More
The biomarkers may help more quickly predict cardiomyopathy in high-risk, asymptomatic childhood cancer survivors.Â
Read More
A two-step screening protocol can effectively identify which patients with Type 2 diabetes need medication to prevent heart failure.
Read More